Development and validation of a nomogram for incorporating F-FDG PET/CT spleen uptake for predicting prognosis in elderly esophageal cancer patients treated with radiotherapy.

Background: There is currently no widely accepted prognostic model specifically for elderly patients with esophageal squamous cell carcinoma (ESCC) undergoing radiotherapy. This study aimed to develop a nomogram incorporating metabolic imaging parameters from F-fluorodeoxyglucose positron emission tomography-computed tomography (F-FDG PET/CT) to predict overall survival (OS) in this patient population. The clinical need for such a prediction model is significant given the challenges of treatment planning in elderly patients with ESCC undergoing radiotherapy.

X-ray Activated Nanoprodrug for Visualization of Cortical Microvascular Alterations and NIR-II Image-Guided Chemo-Radiotherapy of Glioblastoma.

The permeability of the highly selective blood-brain barrier (BBB) to anticancer drugs and the difficulties in defining deep tumor boundaries often reduce the effectiveness of glioma treatment. Thus, exploring the combination of multiple treatment modalities under the guidance of second-generation near-infrared (NIR-II) window fluorescence (FL) imaging is considered a strategic approach in glioma theranostics. Herein, a hybrid X-ray-activated nanoprodrug was developed to precisely visualize the structural features of glioma microvasculature and delineate the boundary of glioma for synergistic chemo-radiotherapy.

F-FDG PET/CT and MR imaging features of liver metastases in gastrointestinal stromal tumors: a cross-sectional analysis.

Background: Early detection of gastrointestinal stromal tumor (GIST) liver metastases is crucial for the management and prognosis. In our experience, GIST liver metastases can display hypermetabolism on F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) and marked enhancement on magnetic resonance imaging (MRI), which are uncommon in other tumors before treatment. Most literature focus on the imaging evaluation, prognosis after treatment and less is known about imaging features on both imaging methods before treatment.

Value of F-FDG PET/CT for differentiating diagnosis between malignant and benign primary gastric gastrointestinal mesenchymal tumors: a single-center retrospective study.

Background: Malignant primary gastric gastrointestinal stromal tumors (gGISTs) without treatment with imatinib are prone to bleeding and peritoneum implantation during operation. Therefore, preoperative assessment of the malignant potential of gGIST is essential. The use of F-fluorodeoxyglucose (F-FDG) positron emission tomography (PET) combined with computed tomography (PET/CT) as a non-invasive tool for diagnosis, staging and prognosis evaluation in oncology, may also be useful for gGISTs.